Lupin is currently trading at Rs. 915.30, up by 7.60 points or 0.84% from its previous closing of Rs. 907.70 on the BSE.
The scrip opened at Rs. 917.50 and has touched a high and low of Rs. 923.55 and Rs. 908.05 respectively. So far 60560 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 923.55 on 05-Jun-2020 and a 52 week low of Rs. 505.00 on 13-Mar-2020.
Last one week high and low of the scrip stood at Rs. 923.55 and Rs. 845.60 respectively. The current market cap of the company is Rs. 41337.20 crore.
The promoters holding in the company stood at 46.92%, while Institutions and Non-Institutions held 39.23% and 13.85% respectively.
Lupin and Mylan N.V. have received European Marketing Authorization for Nepexto, a biosimilar to Enbrel (etanercept), for all indications of the reference product including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis (including ankylosing spondylitis and nonradiographic axial spondyloarthritis), plaque psoriasis and paediatric plaque psoriasis.
The regulatory approval follows the adoption of a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) in March this year, which was based on a biosimilarity assessment including preclinical and clinical studies demonstrating bioequivalence to Enbrel. In addition, a phase 3 clinical study in patients with moderatetosevere active rheumatoid arthritis confirmed equivalence of Nepexto to Enbrel in terms of efficacy, safety and immunogenicity.
Lupin is an innovationled transnational pharmaceutical company headquartered in Mumbai, India.